· Executive Brief
World Psoriasis Day 2026
Use the observance to align communication, service routes, community partners, measures, and accountable follow-through.
Leadership signal
Recognition becomes useful when leaders inspect the real route.
Leaders can use the campaign window to bring partners around one operating map. Clarify the intended audience, approved message, receiving channels, accountable teams, transition points, and the small set of locally defined signals that will show whether the route worked.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Psoriatic disease is a system problem, not a single skin visit
Psoriasis affects 3.0% of U.S. adults aged 20 years or older, according to a nationally representative analysis of 12,625 participants examined between 2011 and 2014.[15] The same analysis found no significant change in prevalence since 2003, and prevalence was similar in women and men.[15] For health systems, that means steady demand, not a seasonal surge that a single campaign can absorb.
The operating challenge is that psoriatic disease rarely stays in one department. Joint symptoms belong to rheumatology, cardiometabolic risk to primary care, emotional strain to behavioral health, and treatment approval to pharmacy and payer teams. Each owner runs its own queue, and the patient carries the connections between them. A person whose skin is well controlled can still have untreated joint inflammation, unscreened blood pressure or unaddressed anxiety. Leaders rarely see that pattern, because each department reports its own volumes rather than the patient’s whole route. World Psoriasis Day is a useful moment to look at that route as a whole.
The mental health load alone is large. A meta-analysis of 101 articles reported that 34% of people with psoriasis had anxiety symptoms.[13] In case-control studies, the odds of anxiety symptoms were 2.51 times those of people without psoriasis.[13] Pooled prevalence was 15% for social anxiety disorder and 11% for generalized anxiety disorder.[13] Those numbers belong in a staffing and referral conversation, not only a clinical one.
This section and the six that follow add the evidence base behind the executive guidance already on this page. They describe where the route breaks, who carries the work, and what leaders can measure. They do not offer individual medical advice, and every figure is tied to its source and setting. Leaders can use them to choose which handoff to test first and which measure will show whether it improved.
Current evidence
What the research says about hidden disease, missed screening and treatment gaps
The first gap is hidden joint disease. In a quality improvement program across 26 dermatology clinics, 6,473 patients with psoriasis had no recorded psoriatic arthritis diagnosis over 27 months.[2] Only 37.2% of them completed an arthritis screening tool, and 12.5% screened positive and completed a follow-up symptom measure.[2] Of patients whose symptom scores were above the program threshold, 44.4% were subsequently diagnosed with psoriatic arthritis.[2] The program’s authors noted that psoriatic arthritis is undiagnosed in up to 41% of cases.[2]
When joint disease is recognized, it is often recognized late. A nationwide study of 1,134 patients with psoriatic arthritis in Turkey reported a mean diagnostic delay of 35.1 months and a median of 12 months.[9] Only 39.15% were diagnosed within three months of symptom onset, and 67.02% within 24 months.[9] The median delay did fall from 60 months before 2010 to 24 months in 2015 to 2019, which suggests that the gap responds to attention.[9]
Cardiovascular risk screening is uneven across the specialties that see patients with psoriasis. In an online survey of 299 physicians in Spain, 74.6% reported screening patients with psoriasis for smoking, 37.8% for hypertension, 80.3% for dyslipidemia and 79.6% for diabetes.[11] Only 28.4% screened for all four, and 24.4% reported calculating 10-year cardiovascular risk.[11] Respondents included 103 dermatologists, 94 rheumatologists and 102 primary care physicians.[11] Among primary care physicians, 61.2% reported not being aware of the psoriasis and cardiovascular disease association, its screening recommendations, or both.[11]
Treatment continuity is the third gap. A meta-analysis of 55 observational studies found pooled adherence to biologic drugs of 0.61 and pooled persistence of 0.63 among adults with psoriasis.[14] The authors described both proportions as suboptimal.[14] Low continuity is not limited to biologics: in a large phototherapy trial, adherence to office-based treatment was 15.9%.[7]
Taken together, the evidence shows that tools for detection, screening and treatment exist. The weak points are completion, handoff and continuity, which are operating problems that leaders can see and assign. Each gap also has a different natural owner: dermatology for detection, rheumatology for confirmation, primary care for cardiometabolic risk and pharmacy for continuity. None of these studies describes a gap that one department could close alone. The practical lesson is to measure each gap as a completion rate with a named denominator and a named owner.
Figure 1
Mean biologic approval waits ranged from 7.3 to 41.3 days by insurance type
Mean wait for biologic approval, in days, by insurance type. Values are copied from the cited studies [12]; none is estimated.
Data note. All four values come from the same study, setting and outcome definition, so they can be compared directly within that study, but subgroup sizes are not reported in the abstract and the pattern may differ in other systems.
Limitation. Single academic health system in Miami with 101 patients; mean waits can be driven by a few long cases, and payer mix and prior authorization rules vary by region.
Figure data (4 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Medicare | 7.3% | Mean wait for biologic approval, Medicare patients; 101 patients with psoriasis or psoriatic arthritis at one academic health system in Miami | [12] |
| Medicaid | 11.3% | Mean wait for biologic approval, Medicaid patients; same single-system review | [12] |
| Preferred provider organization | 37% | Mean wait for biologic approval, PPO patients; same single-system review | [12] |
| Health maintenance organization | 41.3% | Mean wait for biologic approval, HMO patients; same single-system review | [12] |
Continuum of care
Where the route from skin to joints to heart breaks down
The continuum for psoriatic disease runs through at least four settings: primary care, dermatology, rheumatology and cardiometabolic prevention. Each transfer is a point where a symptom can be noted but not acted on. The research identifies several of these points with unusual clarity. For executives, the useful question is not whether each service performs well on its own. It is whether a patient identified in one setting is accepted in the next.
Screening without referral is the first break. In the 26-clinic program, 24.3% of patients who completed the symptom measure scored above the program threshold.[2] Only 24.7% of those patients were referred to rheumatology.[2] A positive screen that does not produce an accepted referral leaves the organization with documentation of risk but no movement of responsibility. A short review of recent positive screens can show leaders how often this happens locally.
Sequence of symptoms is a second break. In the Turkish cohort, arthritis symptoms that appeared before skin manifestations were associated with delayed diagnosis (odds ratio 1.72), as was lower education (odds ratio 2.63).[9] Patients whose joint pain comes first may never be routed to a clinician who connects it to psoriasis.
Joint clinics show what a deliberate handoff can change. A combined rheumatology and dermatology clinic in Portugal saw 505 patients over 802 visits, and diagnostic uncertainty was the main referral reason for 56.4% of them.[6] A definitive psoriatic arthritis diagnosis was made in 28.9% of those uncertainty referrals, and treatment was modified for 78.9% of the patients with confirmed disease.[6] The clinic both confirmed hidden disease and redirected patients whose symptoms had other causes. Its records span November 2010 to February 2021, so the model was sustained for more than a decade.[6]
The cardiometabolic handoff is the weakest link. In the Spanish survey, 12.6% of dermatologists and 37.2% of rheumatologists reported prescribing statins.[11] Among primary care physicians, 67.6% did not treat psoriasis as a risk-enhancing factor for statin decisions.[11] Without a named receiver, cardiovascular risk identified in a skin clinic can easily stay there. The same logic applies to emotional health. With anxiety symptoms reported in 34% of people with psoriasis in pooled studies, a route that ends at the skin clinic leaves predictable need without a receiver.[13]
Figure 3
Why the pathway breaks
People
- Few dermatologists in rural areas
- Primary care teams unaware of cardiovascular association
- Limited staff time to complete screening tools
Process
- Positive arthritis screens not converted to referrals
- No named owner for cardiovascular risk follow-up
- Joint symptoms that precede skin signs routed away from psoriasis care
Technology
- Screening tools not embedded in the record
- No shared tracking of referral acceptance
- Home treatment options not supported remotely
Environment
- Long travel distances for rural patients
- Work demands that patients describe as part of living with psoriasis
- Stigma that discourages disclosure
Policy
- Prior authorization delays that differ by payer
- Inconsistent language access
- Biologic access gaps for people with skin of color
Measurement
- Completion not tracked past the first screen
- Wait times not stratified by payer, race or rurality
- Adherence and persistence not reviewed after approval
Unranked qualitative cause-and-effect diagram for the outcome in the box: People with psoriasis do not reach timely joint, cardiometabolic and mental health care or stay on effective treatment after diagnosis Causes are assembled from the cited literature [2], [3], [4], [8], [9], [10], [11], [12], [14]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Few dermatologists in rural areas; Primary care teams unaware of cardiovascular association; Limited staff time to complete screening tools |
| Process | Positive arthritis screens not converted to referrals; No named owner for cardiovascular risk follow-up; Joint symptoms that precede skin signs routed away from psoriasis care |
| Technology | Screening tools not embedded in the record; No shared tracking of referral acceptance; Home treatment options not supported remotely |
| Environment | Long travel distances for rural patients; Work demands that patients describe as part of living with psoriasis; Stigma that discourages disclosure |
| Policy | Prior authorization delays that differ by payer; Inconsistent language access; Biologic access gaps for people with skin of color |
| Measurement | Completion not tracked past the first screen; Wait times not stratified by payer, race or rurality; Adherence and persistence not reviewed after approval |
Access
Access depends on geography, payer rules and where treatment happens
Geography shapes access before any appointment is booked. A claims study examined 179,688 U.S. adults with psoriasis who had an advanced therapy claim between 2015 and 2019.[8] It found that 41% of urban patients had access to five or more dermatologists, compared with 7% of rural patients.[8] Only 2% of urban patients sought care outside their local area, compared with 75% of rural patients.[8] Advanced therapy use was below 17% in every state.[8] For a system with rural clinics, the dermatology waitlist is therefore only part of the access picture, because many patients are already traveling outside their area.
Payer rules add a second layer of delay. One academic health system in Miami reviewed 101 patients with psoriasis or psoriatic arthritis.[12] The mean wait for biologic approval was 7.3 days for Medicare patients and 11.3 days for Medicaid patients.[12] The mean wait was 37 days for patients with preferred provider organization coverage and 41.3 days for those in health maintenance organizations.[12] Prior authorization was a predictor of longer approval waits.[12]
Same-day approval varied just as widely in that study: 63% for Medicare carriers, 40% for Medicaid, 23.7% for health maintenance organizations and 11.5% for preferred provider organizations.[12] For a revenue cycle or specialty pharmacy leader, those differences point to a work queue that can be measured by payer and staffed accordingly. Approval delays also affect continuity, because a patient who waits weeks to start therapy may meet the same queue again at renewal or when switching treatment.
Where treatment happens also matters. The LITE trial randomized 783 patients across 42 U.S. dermatology practices to home-based or office-based narrowband UV-B phototherapy.[7] At week 12, 32.8% of the home group and 25.6% of the office group had clear or almost clear skin.[7] Adherence was 51.4% at home versus 15.9% in the office.[7] No patients in either group discontinued because of adverse events.[7] The trial included a range of skin phototypes, with 10.6% of participants in types V or VI.[7]
These findings suggest that access is not a single wait-time number. It combines distance, payer friction and the burden of repeated visits, and each component has a different owner inside the organization. Leaders can separate those components in their own data, assign each one, and track whether the slowest piece improves first.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Define the purpose
- Align the entry point
- Link prevention and access
- Manage response
- Review the campaign
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Define the purpose
Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise.
Align the entry point
Connect every communication channel to current information and a clearly identified receiving role or team.
Link prevention and access
Connect approved prevention communication to clear entry points, designated receiving services, transition ownership, and follow-through.
Manage response
Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them.
Review the campaign
Compare intended action with local process signals and partner feedback, then document the improvement to carry forward.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Define the purpose | Name the audience, intended action, approved message, and limits of what the campaign can responsibly promise. |
| Align the entry point | Connect every communication channel to current information and a clearly identified receiving role or team. |
| Link prevention and access | Connect approved prevention communication to clear entry points, designated receiving services, transition ownership, and follow-through. |
| Manage response | Keep questions, referrals, exceptions, and unresolved work visible until an accountable receiver accepts them. |
| Review the campaign | Compare intended action with local process signals and partner feedback, then document the improvement to carry forward. |
Equity and trust
Equity requires looking past headline parity
National prevalence data show that psoriasis was most common among White adults and least common among Black adults, and that insurance status was not associated with prevalence.[15] Lower recorded prevalence is not the same as lower need, and the research on people with skin of color explains why.
An evidence-based review concluded that plaque psoriasis is less prevalent in people with skin of color but tends to be more severe.[3] The same review found that people with skin of color are less likely to receive biologic treatment and experience a worse quality-of-life impact than White populations.[3] The authors also noted that race, ethnicity and skin of color are defined inconsistently, and that evidence from outside North America is limited.[3] For a health system, the practical question is whether its own severity assessments, clinical photographs and treatment decisions perform equally well across skin tones.
Aggregate statistics can hide these patterns. A national analysis of 1,802,720 adult inpatient admissions with psoriasis in 2020 compared systemic medication prescription between non-white and white patients.[5] Hispanic, Asian or Pacific Islander, and Native American patients had significantly lower odds of systemic medication prescription than white patients.[5] All non-white racial groups also had significantly longer estimated lengths of stay than white patients.[5] The authors tied differences in medication choice to a heavier inpatient burden for non-white patients, which leaves room for local review of who receives systemic therapy.[5]
Lived experience fills in what the numbers cannot. A qualitative study of 30 Latine adults with moderate to severe psoriasis at an urban safety-net hospital found that 73% preferred Spanish.[4] The six themes it identified included illness perception, reliance on family networks, impact on work life and barriers to quality care.[4] The authors concluded that participants viewed biologic medications positively and were interested in taking part in biomedical research.[4] Interpreter access, clinic hours and clear cost conversations are the operating levers most directly connected to those themes.
Place affects experience as well. In a study of 122 patients with plaque psoriasis, rural residence was associated with higher scores on two stigmatization domains, sensitivity to others’ attitudes and secretiveness.[10] Combined with the rural access gap, that finding suggests rural patients may face both fewer clinicians and more reason to stay quiet. National parity findings are not a substitute for local review, so leaders should stratify access and continuity measures in their own data.
Human infrastructure
The people and tools that carry psoriatic care across boundaries
Dermatologists are not the only clinicians carrying this work. In the national claims study, the access ratio for internal medicine physicians was 97.1 per 1,000 patients, compared with 4.4 for dermatologists and 3.9 for family practice physicians.[8] Any redesign that assumes every patient will see a dermatologist quickly will fail in much of the country.
That puts a premium on what non-specialists know. In the Spanish survey, 61.2% of primary care physicians were unaware of the cardiovascular association or its screening recommendations, and most did not factor psoriasis into statin decisions.[11] Education for primary care and internal medicine teams is therefore a workforce lever, not a communications extra. These clinicians are also a likely first contact for joint pain that appears before skin disease, a pattern linked to slower diagnosis.[9]
Embedded tools can make the right action easier for a busy clinician. The 26-clinic program built its arthritis screen and symptom measure into the electronic medical record and repeated the symptom measure for 493 patients.[2] Their mean score improved from 2.80 at baseline to 2.53 at the most recent assessment.[2] The low completion rate in the same program shows that tools still need staff time, prompts and ownership to work.[2]
Joint clinics redistribute expertise. In the Portuguese clinic, patients without psoriatic arthritis were often found to have other conditions, including peripheral osteoarthritis (70 patients), fibromyalgia (22) and carpal tunnel syndrome (19).[6] That sorting function can protect rheumatology capacity by directing patients to the right service. Among the 308 patients with confirmed psoriatic arthritis, treatment changes were made for uncontrolled skin activity in 58.0% and for musculoskeletal activity in 34.5%.[6] Most treatment changes (56.4%) were made because of lack of efficacy.[6] Both specialties, in other words, had decisions to make in the same visit.
Home treatment changes who does the work. In the LITE trial, home phototherapy outperformed office-based treatment on adherence while producing no discontinuations for adverse events.[7] Moving care home shifts effort from clinic staff to device logistics, patient teaching and remote follow-up, which require their own roles and budgets. Leaders who adopt home models should plan for that work explicitly rather than assume it disappears. Nurses, medical assistants and pharmacists usually run screening prompts, prior authorization work and home treatment teaching, so their capacity belongs in the same plan.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Message alignment
Do channels and partners communicate one current and appropriately bounded route?
- Candidate local measure
- Content review status, conflicting instructions, corrections, and unresolved questions.
Executive guidance · Signal
Response ownership
Does every campaign-generated request reach an accountable receiver?
- Candidate local measure
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
Executive guidance · Signal
Prevention-to-access alignment
Do campaign messages lead to current, usable, and appropriately bounded access instructions?
- Candidate local measure
- Locally defined conflicting instructions, misroutes, repeat contacts, unaccepted handoffs, and communication corrections.
Executive guidance · Signal
Action closure
Did leaders complete and verify the improvement selected for the campaign window?
- Candidate local measure
- Assigned action, status, evidence of completion, and post-action review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Message alignment | Executive sponsor and operational lead |
| Response ownership | Operational owner and participating teams |
| Prevention-to-access alignment | Sending and receiving owners |
| Action closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Confirm the designated receiving service and avoid language that promises a determination, timing, or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Message alignment | Do channels and partners communicate one current and appropriately bounded route? | Executive sponsor and operational lead | At campaign launch and close |
| Response ownership | Does every campaign-generated request reach an accountable receiver? | Operational owner and participating teams | At a locally defined cadence |
| Prevention-to-access alignment | Do campaign messages lead to current, usable, and appropriately bounded access instructions? | Sending and receiving owners | At a locally defined cadence |
| Action closure | Did leaders complete and verify the improvement selected for the campaign window? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable psoriatic disease pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Annual arthritis screen for patients with psoriasis | Undetected joint disease progresses before diagnosis | Dermatology medical director | Share of patients with psoriasis with a completed screen in the past 12 months |
| Positive screen converted to an accepted rheumatology referral | Risk is documented but responsibility never moves | Dermatology and rheumatology service line leads | Share of positive screens with an accepted referral and scheduled visit |
| Named owner for cardiovascular risk screening | Blood pressure, lipid, glucose and smoking checks fall between specialties | Primary care medical director with dermatology lead | Share of patients with all four risk factors documented |
| Prior authorization queue tracked by payer | Long approval waits delay treatment start | Specialty pharmacy director and revenue cycle lead | Mean and median days to approval and same-day approval rate by payer |
| Biologic continuity review after approval | Patients stop or interrupt therapy without follow-up | Specialty pharmacy and dermatology nursing leads | Persistence at 6 and 12 months, stratified by payer and demographics |
| Language and rural access review | Patients facing distance, language or stigma barriers drop out | Chief health equity officer | Wait times and completion stratified by language, rurality, race and insurance |
Control points derived from the cited evidence [2], [4], [8], [11], [12], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communication that builds activation and reduces stigma
Structured messaging can change how engaged patients are. A randomized trial at a tertiary hospital dermatology clinic in Australia included 111 adults with psoriasis in a six-month text-messaging program sending four messages a week.[1] Compared with standard care, the program raised patient activation scores by 10.8 points and physical activity by 127.9 minutes per week, and it lowered body mass index by 1.0 kg/m².[1] Knowledge of the link between psoriasis and cardiovascular disease also improved.[1]
The same trial is a useful caution. It found no significant differences in lipid levels, hemoglobin A1c, smoking, dermatology-specific quality of life or psoriasis severity.[1] Messaging moved knowledge and behavior over six months, but it did not replace clinical follow-through on measured risk factors. Because a program like this runs between visits, it can extend contact without adding appointments, provided someone owns the clinical results it surfaces.
Stigma shapes whether people speak up at all. Among 122 patients with plaque psoriasis, the mean score on a 6-item stigmatization scale was 6.4 points.[10] The mean on a 33-item feelings of stigmatization questionnaire was 81.3 points.[10] Public messages that treat psoriasis as common, manageable and visible across skin tones can lower the cost of asking for help. Images and descriptions should show the disease across skin tones. That matters because severity, treatment and quality-of-life patterns differ for people with skin of color.[3]
Language access is part of the message, not a translation step at the end. Most participants in the Latine safety-net study preferred Spanish, and the authors called for future work to assess educational interventions.[4] Observance communication should be tested with the communities it is meant to reach before it is published. A review of draft materials by a patient advisory group or community partner that includes speakers of the languages served is a practical start.
Emotional burden deserves a clear and calm route. Given the reported 34% prevalence of anxiety symptoms, campaigns can name where emotional support is available alongside skin and joint services.[13] The goal is a message that leads to an owned next step rather than a general reassurance. Pairing skin, joint and emotional support information in one place also mirrors how patients experience the disease. Messages about joint and cardiovascular risk should also point only to services that can see the patient, given the specialist gaps described above.
Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how World Psoriasis Day communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Compare one prevention message with the real access route and correct a verified mismatch.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how World Psoriasis Day communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Compare one prevention message with the real access route and correct a verified mismatch. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Day observance
Turn World Psoriasis Day into accountable action.
Use the observance to align communication, service routes, community partners, measures, and accountable follow-through.
Leadership focus
Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, prevention access, evaluation navigation, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review representation across skin tones, language, digital access, transportation, cost, disability, and geographic access.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, primary care, specialty services, community partners, and communications teams. Find one unclear information, delayed connection, or a referral without ownership, then test the locally approved route from entry through acknowledged follow-through.
- Define the purpose
- Align the entry point
- Link prevention and access
- Manage response
- Review the campaign
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Content review status, conflicting instructions, corrections, and unresolved questions.
- Routing, acknowledgment, repeat contact, unresolved work, and escalation signals.
- Locally defined conflicting instructions, misroutes, repeat contacts, unaccepted handoffs, and communication corrections.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Public Health and Community Partners
Staff communication template
During World Psoriasis Day, our organization will connect awareness with a practical review of the information, prevention access, evaluation navigation, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
World Psoriasis Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Smith A, Dixit I, Zhang L, Marschner S, Min H, Chow CK. Text Messaging for Cardiovascular Risk Prevention in Psoriasis: A Randomized Clinical Trial. JAMA Dermatology. 2026;162(7):675-684. https://doi.org/10.1001/jamadermatol.2026.1070
- 2.Romanelli S, Ball GD, Hamade H, Zundell MP, Shin S, Senthilkumaran T, et al. Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement Initiative. Journal of Drugs in Dermatology. 2025;24(8):777-781. https://doi.org/10.36849/jdd.9210
- 3.Gkini MA, Nakamura M, Alexis AF, Londoño-Garcia A, van de Kerkhof PCM, Doss N, et al. Psoriasis in People With Skin of Color: An Evidence-Based Update. International Journal of Dermatology. 2025;64(4):667-677. https://doi.org/10.1111/ijd.17651
- 4.Gonzalez N, Wilkerson K, Castillo Valladares H, Sanchez-Anguiano ME, Chang AY, Amerson EH. Latine Patients’ Beliefs, Attitudes, and Experience With Psoriasis. JAMA Dermatology. 2025;161(3):291-298. https://doi.org/10.1001/jamadermatol.2024.5391
- 5.Desai R, Irwin C, McCune M, Davis M. Racial disparities in length of hospitalization and systemic medication utilization in patients with psoriasis. Archives of Dermatological Research. 2025;317(1):1-5. https://doi.org/10.1007/s00403-024-03623-8
- 6.Matos CO, Cunha-Santos F, Silva A, Alpalhão M, Filipe P, Fonseca J, et al. Rheumatology and Dermatology Multidisciplinary Clinic Improves Diagnostic Precision and Treatment Decisions in Patients Suspected or Diagnosed with Psoriatic Arthritis. Journal of Multidisciplinary Healthcare. 2024;17:6143-6151. https://doi.org/10.2147/JMDH.S486029
- 7.Gelfand JM, Armstrong AW, Lim HW, Feldman SR, Johnson SM, Claiborne WCC, et al. Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatology. 2024;160(12):1320-1328. https://doi.org/10.1001/jamadermatol.2024.3897
- 8.Seigel L, Shoaib S, Maughn K, Foster M, Shah S, Batchu L, et al. Health disparities in psoriasis: geographic barriers to access in the United States. Journal of Dermatological Treatment. 2024;35(1):2365820. https://doi.org/10.1080/09546634.2024.2365820
- 9.Kılıç G, Kılıç E, Tekeoğlu İ, Sargın B, Cengiz G, Cüzdan Balta N, et al. Diagnostic delay in psoriatic arthritis: insights from a nationwide multicenter study. Rheumatology International. 2023;44(6):1051-1059. https://doi.org/10.1007/s00296-023-05479-z
- 10.Jankowiak B, Krajewska-Kułak E, Jakoniuk M, Khvorik DF. Stigmatization among Patients with Plaque Psoriasis. Journal of Clinical Medicine. 2023;12(19):6425. https://doi.org/10.3390/jcm12196425
- 11.Berna-Rico E, Abbad-Jaime de Aragon C, Garcia-Aparicio A, Palacios-Martinez D, Ballester-Martinez A, Carrascosa JM, et al. Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. Acta Dermato-Venereologica. 2023;103:adv5087. https://doi.org/10.2340/actadv.v103.5087
- 12.Vazquez T, Forouzandeh M, Lin D, Chin F, Perez M, Caban-Martinez A, et al. Insurance delays in the approval of biologic medications for patients with psoriasis and psoriatic arthritis. Archives of Dermatological Research. 2022;315:1401-1403. https://doi.org/10.1007/s00403-022-02457-6
- 13.Jalenques I, Bourlot F, Martinez E, Pereira B, D’Incan M, Lauron S, et al. Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysis. Acta Dermato-Venereologica. 2022;102:adv00769. https://doi.org/10.2340/actadv.v102.1386
- 14.Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M, et al. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine. 2022;11(6):1506. https://doi.org/10.3390/jcm11061506
- 15.Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatology. 2021;157(8):940-946. https://doi.org/10.1001/jamadermatol.2021.2007
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| U.S. prevalence and demographic distribution of psoriasis | [15] | 2021 | Executive opening | National examination data from 2011 to 2014 in noninstitutionalized adults; self-reported diagnosis. |
| Anxiety disorders and symptoms among people with psoriasis | [13] | 2022 | Executive opening | Pooled estimates across heterogeneous studies and measures; includes children and adults. |
| Undetected psoriatic arthritis and screening-to-referral completion in dermatology | [2] | 2025 | Current evidence | Quality improvement report from participating clinics without a control group; completion denominators differ by step. |
| Diagnostic delay in psoriatic arthritis and associated factors | [9] | 2023 | Current evidence | Turkish multicenter registry; recall of symptom onset; may not generalize to U.S. systems. |
| Cardiovascular risk screening and statin prescribing by specialty | [11] | 2023 | Current evidence | Self-reported online survey of physicians in Spain; response bias possible. |
| Adherence and persistence to biologic therapy | [14] | 2022 | Current evidence | Observational studies with varied definitions of adherence and persistence. |
| Joint dermatology-rheumatology clinic diagnostic and treatment yield | [6] | 2024 | Continuum of care | Single-center cross-sectional study in Portugal; referred population; no comparison group. |
| Geographic access to psoriasis clinicians and advanced therapy use | [8] | 2024 | Access | Claims data limited to patients with an advanced therapy claim; access ratios depend on area definitions. |
| Biologic approval waits and same-day approval by insurance type | [12] | 2022 | Access | Single academic health system in Miami; 101 patients; short report. |
| Home versus office phototherapy effectiveness and adherence | [7] | 2024 | Access | Pragmatic trial in 42 U.S. practices; outcomes at 12 weeks; patients aged 12 and older. |
| Disparities in severity, treatment and evidence for people with skin of color | [3] [5] [15] | 2025, 2021 | Equity and trust | Narrative evidence review with inconsistent race definitions; inpatient analysis covering hospitalized patients in a single year. |
| Latine patient experience, language preference and stigma | [4] [10] | 2025, 2023 | Equity and trust | Qualitative study of 30 safety-net patients; stigma survey of 122 patients with plaque psoriasis. |
| Text-messaging program effects on activation and cardiovascular risk behaviors | [1] | 2026 | Public communication | Single-center trial in Australia; six-month follow-up; no effect on lipids, hemoglobin A1c or severity. |
About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.